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Introduction
Toxic Epidermal Necrolysis (TEN) is a rare and acute
life threatening mucocutaneous reaction characterized
by extensive necrosis and detachment of the epidermis,
most commonly drug induced. Lenalidomide is a deriva-
tive of thalidomide used in treatment of multiple mye-
loma, myelodysplastic syndromes. We present a case of
TEN in lenalidomide treated patient of multiple mye-
loma with HIV.
Case Report
A 58 year old male, a k/c/o chronic kidney disease and
multiple myeloma presented to the OPD with diffuse red-
ness and peeling of the skin of 3 days duration associated
with intense burning sensation and erosions in the mouth
and genitalia. Patient was started on T. Lenalidomide
16 days ago for multiple myeloma. In view of an episode
of herpes zoster in the past HIV testing was done which
was found to be positive. O/E- multiple erosions were pre-
sent over the scalp, face trunk and genitalia. There was
approximately 60-80% of epidermal detachment and
SCORTEN was 4. Nikolsky’s sign positive.
Discussion
Lenalidomide is used as an alternative for thalidomide for
its lesser incidence of side effects. HIV infected individuals
are deficient in the enzyme glutathione peroxidase which
is essential for drug metabolism. Only two cases of SJS,
TEN to lenalidomide have been reported so far. The case
is presented for its rarity and association with HIV.
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